XERS Latest Press Releases

-- November 2, 2026 --

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors Business Wire 8:00 AM

-- October 22, 2026 --

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 Business Wire 8:00 AM

-- October 15, 2026 --

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings Business Wire 8:00 AM

-- October 2, 2026 --

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- September 9, 2026 --

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism Business Wire 8:30 AM

-- August 26, 2026 --

Xeris Announces Details for XP-8121 Program Overview Webinar Business Wire 7:30 AM

-- August 6, 2026 --

Xeris Biopharma Reports Second Quarter 2026 Financial Results Business Wire 7:00 AM

-- July 23, 2026 --

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 Business Wire 7:30 AM

-- July 2, 2026 --

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 10:40 PM

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:05 PM

-- June 30, 2026 --

Xeris Announces Updates to Its Board of Directors Business Wire 7:00 AM

-- June 11, 2026 --

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS Business Wire 4:39 PM

Xeris Biopharma Announces Private Exchange of Convertible Notes Business Wire 7:00 AM

Market Data Delayed 15 Minutes